Short Interest in Celcuity, Inc. (NASDAQ:CELC) Expands By 20.9%

Celcuity, Inc. (NASDAQ:CELC) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 8,853,129 shares, a growth of 20.9% from the December 15th total of 7,321,648 shares. Based on an average daily trading volume, of 840,129 shares, the short-interest ratio is presently 10.5 days. Approximately 22.7% of the company’s shares are sold short. Approximately 22.7% of the company’s shares are sold short. Based on an average daily trading volume, of 840,129 shares, the short-interest ratio is presently 10.5 days.

Celcuity Stock Performance

Shares of NASDAQ CELC opened at $106.96 on Monday. The stock has a market cap of $4.95 billion, a PE ratio of -29.14 and a beta of 0.25. Celcuity has a 1 year low of $7.57 and a 1 year high of $116.44. The firm has a fifty day moving average price of $99.87 and a 200-day moving average price of $65.71. The company has a debt-to-equity ratio of 2.74, a current ratio of 12.26 and a quick ratio of 12.26.

Celcuity (NASDAQ:CELC) last released its earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.13. Equities analysts anticipate that Celcuity will post -2.62 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CELC. Jefferies Financial Group boosted their target price on Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a research report on Tuesday, December 2nd. Wolfe Research initiated coverage on shares of Celcuity in a report on Tuesday, November 18th. They issued an “outperform” rating and a $110.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, October 8th. Craig Hallum lifted their price target on shares of Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, Wall Street Zen downgraded shares of Celcuity from a “hold” rating to a “sell” rating in a research report on Sunday, October 26th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $105.25.

Insider Buying and Selling

In related news, Director Richard E. Buller sold 3,000 shares of the business’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $105.69, for a total transaction of $317,070.00. Following the transaction, the director owned 6,760 shares in the company, valued at $714,464.40. The trade was a 30.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 15.77% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Ogorek Anthony Joseph NY ADV purchased a new stake in shares of Celcuity during the 3rd quarter worth approximately $27,000. US Bancorp DE raised its position in shares of Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after buying an additional 143 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after acquiring an additional 1,167 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Celcuity by 211.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock valued at $74,000 after acquiring an additional 3,766 shares during the last quarter. Finally, Avanza Fonder AB bought a new stake in Celcuity during the third quarter worth approximately $79,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.